Biotechs Target the GI Tract

Regulatory risk and a mature market for some indications have driven Big Pharma players from the gastrointestinal space. That signals possible biotech opportunity. In this issue, we profile Alvine Pharmaceuticals, Genetic Analysis, Meritage Pharma and Ventrus Biosciences.

Stretched to its full length, the adult gastrointestinal (GI) tract can extend up to 30 feet. An awful lot can go wrong from stem to stern. One outcome: GI pharmaceuticals account for many of the top selling prescription drugs on the market.

Much can also go awry for companies pursuing novel GI agents. Many former GI blockbusters have gone generic or are...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip